vTv Therapeutics Inc. Class A (VTVT) Key Ratios
$33.35
As on 04-Sep-2026 16:00EDT
Market cap
$132 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 216,458.82 | 1,169.36 | 37.83 |
| EBIT | -154.09 | -76.88 | 73.21 | 20.26 | -0.91 |
| Net Profit | -154.09 | -177.04 | 79.59 | 22.93 | -156.71 |
| EPS | -136.72 | -14.61 | 96.44 | 25.74 | 14.52 |
| Book Value | -- | -- | 261.89 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -145,294.69 | -73,065.19 | -17.38 | -- | -2,222.71 |
| Net Margin
| -- | 1,538.04 | -12.92 | -- | -- |
| Return on equity
| 113.26 | 111.17 | -4.35 | -70.40 | 295.84 |
| Return on Capital
| 120.54 | 118.94 | -- | -70.24 | 313.37 |
| Return on Assets
| -69.51 | -67.66 | -7.53 | -42.09 | -74.92 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
-70.24
|
313.37
|
118.51
|
203.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-4.35
Higher than Peers by 35.98
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
-4.35
|
-70.40
|
295.84
|
114.34
|
187.15
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-7.53
Higher than Peers by 23.72
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
-7.53
|
-42.09
|
-74.92
|
-91.51
|
-65.28
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-17.38
Higher than Peers by 65.22
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
-17.38
|
--
|
-2,222.71
|
-288,366.67
|
-1,231.81
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-12.92
Higher than Peers by 78.38
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
-12.92
|
--
|
-1,815.34
|
-225,000.00
|
1,538.04
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
216,458.82
Higher than Peers by 216,404.79
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
216,458.82
|
-1.00
|
112.00
|
-1.00
|
-0.50
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
73.21
Higher than Peers by 74.22
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
73.21
|
-37.47
|
12.90
|
-4.41
|
-41.21
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
79.59
Higher than Peers by 87.13
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
79.59
|
-46.11
|
8.83
|
-5.67
|
-47.56
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
96.44
Higher than Peers by 82.21
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
96.44
|
0.00
|
0.67
|
-0.03
|
-0.21
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
1,411.20
Higher than Peers by 1,421.34
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
1,411.20
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
--
|
0.01
|
-0.02
|
-0.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
--
|
0.01
|
-0.01
|
-0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
12.48
Higher than Peers by 6.67
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
12.48
|
13.54
|
7.34
|
1.00
|
3.52
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
12.48
Higher than Peers by 6.79
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
12.48
|
--
|
--
|
--
|
3.51
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-1,066.17
Lower than Peers by 1,064.08
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
-1,066.17
|
-5,179.00
|
--
|
-1,996.38
|
-1,657.20
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
--
|
6.10
|
1,133.33
|
615.26
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.58
Higher than Peers by 0.52
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
0.58
|
--
|
0.04
|
0.00
|
0.07
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
--
|
29.45
|
254,011.08
|
1,128.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
--
|
--
|
60.88
|
228.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
23,638.52
|
10,288.56
|
13,262.63
|
8,609.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
--
|
--
|
240,809.33
|
-7,252.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
-12.49
|
-4.32
|
-1.18
|
-0.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.62
Lower than Peers by 3.71
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
1.62
|
5.23
|
6.53
|
-0.97
|
-0.13
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.11
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
-2.11
|
-7.98
|
-1.91
|
-0.58
|
0.41
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
132
Lower than Peers by 10
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
132
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|